课题基金 / 基金详情

SHAPE: Morphology Characterisation and Control of Particulate Products: Integrating Multi-scale Image Analysis and Modelling

SHAPE: Morphology Characterisation and Control of Particulate Products: Integrating Multi-scale Image Analysis and Modelling
SHAPE:颗粒产品的形态表征和控制:集成多尺度图像分析和建模
批准号:
EP/H008012/1
负责人:
Xue Wang
金额:
$14.0万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2010
资助国家:
英国
项目状态:
已结题
起止时间:
2010 至 --

项目摘要

项目成果

Xue Wang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Particulate products are made in industries including pharmaceuticals, agro-chemicals, dyes and pigments, food, detergents and formulation additives. It is well known that particle morphology is extremely important to products end-use properties e.g. dissolution rate and bio-availability of pharmaceuticals and processability e.g. flowability. In extreme cases, resulting in a company's loss of the license to make the drug product. However, optimisation and control in formulation and manufacture of the shape distribution of a particle population in a reactor has long been considered to be too challenging to achieve. Therefore, previous efforts have focused on optimising and controlling particle size distribution where the size of a particle is defined as the diameter of a sphere that has the same volume of the particle. This clearly misses important information of particle shape. The group led by Professor Xue Wang has been researching technologies for measurement (using in-process imaging), modeling, and optimisation and control of the shape distribution for a particle population. The research has led to two major breakthrough advance - the development of a multi-scale image analysis technique and a morphological population balance process model, which not only positioned the research in a world leading position, but also created a rare opportunity for commercialisation. A development project is close to be signed with GlaxoSmithKline focusing on analysing the SEM images of pharmaceutical particles with the aim of understanding and minimising batch to batch variation. Other industrial collaborators (AstraZeneca, Syngenta, National Nuclear Laboratory and Pfizer) have also expressed interest in such a commercialised product.In this EPSRC follow-on grant proposal we want to commercialise the technologies and tools developed through the EPSRC funded research. At the end of the 12 moths, we aim to develop a prototype tool that has unique features that no existing system can compete, and can be marketed to potential customers (including end-user customers i.e. particulate product manufacturers; instrument suppliers; research organisations), used to provide data analysis services to customers, and attract new investment for full commercialization and the spin-off company growth.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1021/je400938a
发表时间: 2014-02
期刊: Journal of Chemical & Engineering Data
影响因子: --
作者: [Wen J. Liu;Cai Y. Ma;Shengxiang Feng;X. Wang]
通讯作者: Wen J. Liu;Cai Y. Ma;Shengxiang Feng;X. Wang
Continuous reactive crystallization of pharmaceuticals using impinging jet mixers
使用冲击喷射混合器进行药物的连续反应结晶
DOI: 10.1002/aic.15438
发表时间: 2017-03-01
期刊: AICHE JOURNAL
影响因子: 3.7
作者: [Liu, Wen J., Ma, Cai Y., Wang, Xue Z.]
通讯作者: Wang, Xue Z.
Processing Nanoparticles in Suspension of High Solid Concentration: On-line Characterisation and Process Modelling
  • 批准号:
    EP/H008853/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $42.25万
  • 财政年份:
    2010
  • 负责人:
    Xue Wang
  • 依托单位:
Continuous Hydrothermal Synthesis of Nanomaterials: From Laboratory to Pilot Plant
  • 批准号:
    EP/E040624/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $62.87万
  • 财政年份:
    2008
  • 负责人:
    Xue Wang
  • 依托单位:
Stereo Vision Probe: A New PAT Instrument for Real-time Characterisation of Particulate Systems
  • 批准号:
    EP/E045707/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $43.31万
  • 财政年份:
    2007
  • 负责人:
    Xue Wang
  • 依托单位:
HIGH THROUGHPUT INORGANIC NANOMATERIALS DISCOVERY
  • 批准号:
    EP/D038391/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $18.04万
  • 财政年份:
    2006
  • 负责人:
    Xue Wang
  • 依托单位:
海外基金